Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors

Our aim was to assess the real‐world effectiveness of immune checkpoint inhibitors for treatment of patients with progressive multifocal leukoencephalopathy (PML).

[1]  A. Sommet,et al.  Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions. , 2022, Brain : a journal of neurology.

[2]  A. Sommet,et al.  Outcome of Progressive Multifocal Leukoencephalopathy Treated by Interleukin‐7 , 2022, Annals of neurology.

[3]  M. Wattjes,et al.  Innovative therapeutic concepts of progressive multifocal leukoencephalopathy , 2022, Journal of Neurology.

[4]  R. D. Du Pasquier,et al.  CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[5]  R. D. Du Pasquier,et al.  Advances in Treatment of Progressive Multifocal Leukoencephalopathy , 2021, Annals of neurology.

[6]  Bryan R. Smith,et al.  BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study , 2021, The Lancet Neurology.

[7]  D. Reich,et al.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease , 2020, Nature Reviews Neurology.

[8]  B. Stankoff,et al.  Progressive multifocal leukoencephalopathy on dimethyl fumarate with preserved lymphocyte count but deep T-cells exhaustion , 2020, Multiple sclerosis.

[9]  I. Cortese,et al.  Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. , 2020, Current opinion in virology.

[10]  F. Chapon,et al.  Sustained Response and Rationale of Programmed Cell Death-1-Targeting for Progressive Multifocal Leukoencephalopathy , 2019, Open forum infectious diseases.

[11]  E. Wherry,et al.  Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.

[12]  M. Raftery,et al.  The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance , 2019, Front. Cell. Infect. Microbiol..

[13]  Bryan R. Smith,et al.  Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy , 2019, The New England journal of medicine.

[14]  C. Mengelle,et al.  Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab. , 2019, The New England journal of medicine.

[15]  A. Verma,et al.  Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant – a case series , 2018, Leukemia & lymphoma.

[16]  S. Lewin,et al.  Immune checkpoint blockade in infectious diseases , 2017, Nature Reviews Immunology.

[17]  R. Koup,et al.  Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy , 2017, The Journal of infectious diseases.

[18]  V. Boussiotis.  Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. , 2016, The New England journal of medicine.

[19]  Matheus C. Bürger,et al.  Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy , 2016, Nature.

[20]  Sandra P. Calderon-Copete,et al.  T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. , 2016, Immunity.

[21]  C. Quereda,et al.  Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV‐associated progressive multifocal leucoencephalopathy , 2016, European journal of neurology.

[22]  S. Holland,et al.  Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. Hotchkiss,et al.  Parallels between cancer and infectious disease. , 2014, New England Journal of Medicine.

[24]  Jia Liu,et al.  Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral Infection , 2014, PLoS pathogens.

[25]  H. Lassmann,et al.  In situ evidence of JC virus control by CD8+ T cells in PML-IRIS during HIV infection , 2013, Neurology.

[26]  A. Tager,et al.  Detection of JC Virus-Specific Immune Responses in a Novel Humanized Mouse Model , 2013, PloS one.

[27]  R. Lenkinski,et al.  Metabolic profile of PML lesions in patients with and without IRIS , 2012, Neurology.

[28]  E. Bord,et al.  Increased Program Cell Death–1 Expression on T Lymphocytes of Patients With Progressive Multifocal Leukoencephalopathy , 2012, Journal of acquired immune deficiency syndromes.

[29]  M. Sahraian,et al.  Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy , 2011, Acta Neuropathologica.

[30]  L. Jones,et al.  Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. , 2011, Brain : a journal of neurology.

[31]  D. Costagliola,et al.  Improved Survival of HIV-1-Infected Patients with Progressive Multifocal Leukoencephalopathy Receiving Early 5-Drug Combination Antiretroviral Therapy , 2011, PloS one.

[32]  L. Ngo,et al.  Role of CD4+ and CD8+ T-Cell Responses against JC Virus in the Outcome of Patients with Progressive Multifocal Leukoencephalopathy (PML) and PML with Immune Reconstitution Inflammatory Syndrome , 2011, Journal of Virology.

[33]  P. Massip,et al.  Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV. , 2011, Brain : a journal of neurology.

[34]  Simon Wandel,et al.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. , 2010, The Lancet. Infectious diseases.

[35]  D. Clifford,et al.  Determinants of survival in progressive multifocal leukoencephalopathy , 2009, Neurology.

[36]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[37]  B. Brew.  Faculty Opinions recommendation of PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. , 2009 .

[38]  G. Freeman,et al.  Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade , 2008, Nature.

[39]  D. Clifford,et al.  Frequency and Phenotype of JC Virus-Specific CD8+ T Lymphocytes in the Peripheral Blood of Patients with Progressive Multifocal Leukoencephalopathy , 2007, Journal of Virology.

[40]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[41]  R. D. Du Pasquier,et al.  Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies , 2005, AIDS.

[42]  A. Lazzarin,et al.  Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  M. Kramer,et al.  Progressive multifocal leukoencephalopathy in transplant recipients , 2004, Transplant international : official journal of the European Society for Organ Transplantation.

[44]  M. Kuroda,et al.  A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. , 2004, Brain : a journal of neurology.

[45]  J. Delfraissy,et al.  Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy , 2003, AIDS.

[46]  A. De Luca,et al.  The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. , 2000, The Journal of infectious diseases.

[47]  A. Lazzarin,et al.  Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  R. Levy,et al.  Predictive factors for prolonged survival in acquired immunodeficiency syndrome—associated progressive multifocal leukoencephalopathy , 1998, Annals of neurology.